Curi Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Curi Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-51	Closed	–	–	471
2022 Q2	$0	Buy	+51	New	+$67	﹤0.01%	684

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Curi Wealth Management's LCTX Position: Q3 2022 in Review

Curi Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2022, closing a stake of 51 shares.

Curi Wealth Management first reported a position in LCTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 105 funds tracked by Wall St. Rank hold LCTX as of Q3 2022.

Curi Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q3 2022 after selling out during the quarter.
Curi Wealth Management sold 51 Lineage Cell Therapeutics shares in Q3 2022.
Curi Wealth Management first reported a position in Lineage Cell Therapeutics in Q2 2022 and held it in 1 quarter.
Curi Wealth Management's Lineage Cell Therapeutics position peaked at $0 in Q2 2022.
105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2022.

Based on Curi Wealth Management's 13F filing for Q3 2022, filed 8 Nov 2022.